Dr. Lee Schwartzberg, a leader in Supportive Care Cancer Research, will be giving two oral presentations at the MASCC (Multinational Association of Supportive Care in Cancer) Symposium. This premiere meeting in Supportive Care is being held in Miami, FL, June 26-28, 2014, and is designed to educate and inform an international audience of health care professionals on methods to minimize therapy-induced side effects along with the symptoms and complications associated with cancer.
Dr. Schwartzberg’s presentations will include:
- Phase 3 Trial Results for Rolapitant, a Novel NK-1 Receptor Antagonist, in the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Subjects Receiving Moderately Emetogenic Chemotherapy (MEC)
- Do NK1 Receptor Antagonists (RA) Contribute to Nausea Control? Evaluation of the Novel NEPA Fixed-Dose Combination of NK1 RA + 5-HT3 RA from Pivotal Trials